ABSTRACT Daptomycin exhibits clinical activity in the treatment of infections with Gram-positive organisms, including infections due to methicillin-resistant Staphylococcus aureus . However, little is known about its penetration into bone and synovial fluid. The aim of our study was to assess the penetration of daptomycin into bone and synovial fluid after a single intravenous administration. This study was conducted in 16 patients who underwent knee or hip replacement and received a single intravenous dose of 8 mg of daptomycin per kg of body weight prior to surgery. Plasma daptomycin concentrations were measured 1 h after the end of daptomycin infusion and when bone fragments were removed. Daptomycin concentrations were also measured on bone fragments and synovial fluid collected at the same time during surgery. All samples were analyzed with a diode array–high-performance liquid chromatography (HPLC) method. After a single-dose intravenous infusion, bone daptomycin concentrations were above the MIC of daptomycin for Staphylococcus aureus in all subjects, and the median bone penetration percentage was 9.0% (interquartile range [IQR], 4.4 to 11.4). These results support the use of daptomycin in the treatment of Staphylococcus aureus bone and joint infections.

Daptomycin

Interquartile range

10.1128/aac.02344-14

Cite

Citations (52)

Niveau de preuve du suivi therapeutique pharmacologique du saquinavir

Therapies (2011)

Patrice Muret Caroline Solas

Saquinavir

10.2515/therapie/2011029

Cite

Citations (1)

Subject Index Vol. 16, 2003

Skin Pharmacology and Physiology (2003)

Masaharu Matsukura A. Yajima Fumio Yamazaki Tatsuo Yudate Hiroto Yamada

Bath PUVA therapy

10.1159/000073952

Cite

Citations (0)

Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: In vitro comparison on HaCaT

International Journal of Pharmaceutics (2014)

A Guichard Philippe Humbert Marion Tissot Patrice Muret C. Courderot-Masuyer

HaCaT

Clobetasol propionate

Propidium iodide

10.1016/j.ijpharm.2014.12.066

Cite

Citations (46)

Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application

Journal of Wound Care (2014)

Céline Viennet C. Laurensou Anne-Claude Goydadin B. Faivre Patrice Muret

Objective: To describe an in vitro fibrin clot model that could reliably assess the fibrinolytic activity of enzymatic debriding agents for wound care application. Method: A model of a fibrin clot was reconstructed in vitro by mixture of human fibrinogen and a-thrombin supplemented with factor XIII. These clots were then treated with enzymatic ointments. Fibrinolytic activity was investigated by measuring D-dimer levels, using an automated immunoturbidimetric Liatest D-dimer assay. Results: Collagenase and papain-urea ointments demonstrated fibrinolytic activity which was macroscopically visible. Their effect was identical on the in vitro reconstructed fibrin clot and ex vivo collected wound fibrin clot; collagenase and papain-urea both induced a complete degradation and dissolution of both fibrin clots after 24 hours of treatment. This was associated with an increase in D-dimer concentration. Conclusion: This reconstructed fibrin clot in vitro model has the potential to predict the efficacy of fibrinolytic agents and therefore appears to be a suitable model for in vitro assays. Declaration of interest: This study was supported by a grant from URGO Laboratory.

Wound care

Clot formation

10.12968/jowc.2014.23.2.66

Cite

Citations (2)

Effects of cigarette smoking on the skin of women

Journal of Dermatological Science (2006)

A Petitjean S. Mac‐Mary J.-M. Sainthillier Patrice Muret B. Closs

10.1016/j.jdermsci.2006.02.002

Cite

Citations (12)

Comparison of fluorescence polarization immunoassay and high-performance liquid chromatography methods for assay of teicoplanin: can correlation be improved?

Pathologie Biologie (2004)

Siamak Davani Michel Bérard Bernard Royer Jean‐Pierre Kantelip Patrice Muret

Teicoplanin

Fluorescence polarization immunoassay

10.1016/j.patbio.2004.07.033

Cite

Citations (10)

Binding of 5-methoxypsoralen to blood fractions. Influence of albumin and free fatty acids: an in vitro study.

PubMed (1993)

Patrice Muret Safwat Makki Saı̈k Urien P Agache P Bechtel

The binding of 5-methoxypsoralen (5-MOP) to human serum and blood fractions was studied by equilibrium dialysis associated to high-performance liquid chromatography. 5-MOP serum binding was 95% and kept constant in the range of therapeutic concentrations. Albumin was the main binding protein with one class of binding sites (n = 2.05) and with a moderate affinity constant (Ka = 10,270 M-1). Free fatty acids (FFA) enhanced 5-MOP binding to albumin. Binding to other proteins, alpha 1-acid glycoprotein, gamma-globulins and lipoproteins (LDL, HDL, VLDL) also occurred, but was negligible. 5-MOP bound to red blood cells (RBCs) with a binding index (ratio of intra- to extra-globular 5-MOP concentrations) of 3.84 and 1.48 in buffer and plasma, respectively. 5-MOP distribution in blood was simulated. The free fraction of 5-MOP in blood could be increased in hypoalbuminemia, unchanged in acute inflammation, and decreased by FFA.

Hypoalbuminemia

Binding constant

Serum Albumin

Free fraction

Source

Cite

Citations (3)

[Therapeutic drug monitoring of mycophenolate mofetil, sirolimus and cyclosporine at C2].

PubMed (2003)

Bernard Royer Siamak Davani Michel Bérard J-P Kantelip Patrice Muret

The evolutions in treatments and clinical practices in organ transplantations led to modifications in the therapeutic drug monitoring (TDM) of immunosuppressive drugs. A focus is made regarding the C2 sampling of cyclosporin, as well as the TDM of mycophenolate mofetil and sirolimus. A review of literature about the evolution of drug monitoring, technical methods and sampling strategies is described. Arguments in favour of TDM are thus a decrease in the frequency of both graft rejection and adverse drug reactions, however, new strategies or new targets are needed in new associations or indications.

Sirolimus

Mycophenolate

Therapeutic Drug Monitoring

Drug reaction

Immunosuppressive drug

Source

Cite

Citations (4)